Clinical utility of chromosome genomic array testing for unclassified and advanced-stage renal cell carcinomas

Nicole K. Andeen, Xiaoyu Qu, Tatjana Antic, Scott S. Tykodi, Min Fang, Maria S. Tretiakova

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Context.-Cytogenomic analysis provides a useful adjunct to traditional pathology in the categorization of renal cell carcinomas (RCCs), particularly in morphologically ambiguous cases, but it has disadvantages, including cost. Objective.-To define the clinical scenarios in which this technology has direct clinical applications. Design.-DNA was isolated from paraffin-embedded tissue from 40 selected cases of RCC. Chromosome genomic array testing was performed using the OncoScan. Results.-Of 23 cases of unclassified renal tumors, 19 (83%) were reclassified with incorporation of cytogenetic and histologic features, including 10 as clear cell RCC, 2 as collecting duct carcinoma, 2 as papillary RCC, and 1 as novel TFEB-amplified tumor lacking TFEB translocation. Of 5 tumors with ''hybrid'' oncocytic features, 3 were reclassified as an eosinophilic variant of chromophobe RCC and 1 as oncocytoma. Appropriate staging in 2 patients was determined by identifying distinct, nonshared cytogenetic profiles. Of 11 cases of metastatic clear cell RCC, 7 (63%) had cytogenetic features associated with a poor prognosis. Conclusions.-We identified 5 scenarios in which chromosome genomic array testing has direct clinical utility: (1) to investigate unclassified RCCs, (2) to understand tumors with ''hybrid'' features and ''collision'' tumors, (3) to determine appropriate staging in questions of bilateral tumors and/or metastases, (4) to identify chromosomal aberrations in metastatic clear cell RCCs associated with a worse prognosis, and (5) to identify new entities. This has practical value in our institution, where a molecular profile diagnostically separating morphologically difficult to classify clear cell, papillary, chromophobe, and unclassified RCC influences treatment recommendations and clinical trial eligibility.

Original languageEnglish (US)
Pages (from-to)494-504
Number of pages11
JournalArchives of Pathology and Laboratory Medicine
Volume143
Issue number4
DOIs
StatePublished - Apr 2019

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Fingerprint Dive into the research topics of 'Clinical utility of chromosome genomic array testing for unclassified and advanced-stage renal cell carcinomas'. Together they form a unique fingerprint.

Cite this